21.05.2024 07:30:06 - dpa-AFX: GNW-Adhoc: Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation
Bio and OpenAI are collaborating to build AI-powered software to accelerate drug
development and bring new medicines to patients more efficiently. The three
teams will bring together data, software and tuned models to develop custom,
purpose-built solutions across the drug development lifecycle. This represents a
first collaboration of its kind within the pharma and life sciences industries.
Sanofi will leverage this partnership to provide access to proprietary data to
develop AI models as it continues on its path to becoming the first biopharma
company powered by AI at scale.
Paul Hudson
CEO, Sanofi
"This unique collaboration is the next significant step in our journey to
becoming a pharmaceutical company substantially powered by AI. Next generation,
first-of-its kind AI model customizations will be an important foundation in our
efforts to shape the future of drug development for pharma and for the many
patients waiting for innovative treatments."
OpenAI, the world leader in AI technology, will contribute access to cutting-
edge AI capabilities, including the ability to fine-tune models, deep AI
expertise and dedicated thought partnership and resources.
Brad Lightcap
COO, OpenAI
"There is massive potential for AI to accelerate drug development. We are
excited to collaborate with Sanofi and Formation Bio to help patients and their
families by bringing new medicines to market."
Formation Bio, an AI and tech-driven drug developer with its own pipeline of
drug assets, will provide extensive engineering resources, experience operating
at the intersection of pharma and AI, and its tech-driven development platform
to design, develop and deploy AI technologies across all aspects of the pharma
lifecycle.
Benjamine Liu
Co-Founder & CEO, Formation Bio
"I firmly believe that by combining our strengths, Sanofi, OpenAI and Formation
Bio can reimagine drug development in the pharma industry. By creating and
implementing customized AI agents and models designed for our industry,
companies like Sanofi and Formation Bio can begin to scale with unprecedented
productivity and transform the pace at which we bring new medicines to
patients."
The potential positive impact of AI for patients waiting for new treatments is
tremendous and Sanofi, Formation Bio and OpenAI plan to lead the way for drug
developers.
About Formation Bio
Formation Bio is a tech-driven and AI-native pharma differentiated by radically
more efficient drug development. Advancements in AI and drug discovery are
creating more candidate drugs than the industry can progress because of the high
cost and time of clinical trials. Recognizing that this development bottleneck
may ultimately limit the number of new medicines that can reach patients,
Formation Bio, founded in 2016 as TrialSpark Inc., has built technology
platforms, processes, and capabilities to accelerate all aspects of drug
development and clinical trials. Formation Bio partners, acquires, or in-
licenses drugs from pharma companies, research organizations, and biotechs to
develop programs past clinical proof of concept and beyond, ultimately helping
to bring new medicines to patients.
"Formation Bio" and "TrialSpark" are trademarks of TrialSpark Inc.
About OpenAI
OpenAI is an AI research and deployment company. Its mission is to ensure that
artificial general intelligence benefits all of humanity.
This partnership was led by OpenAI's COO and approved by its independent Board
of Directors.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase
the miracles of science to improve people's lives. Our team, across the world,
is dedicated to transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing treatment
options and life-saving vaccine protection to millions of people globally, while
putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
(mailto:evan.berland@sanofi.com)
Victor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.com
(mailto:victor.rouault@sanofi.com)
Timothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com
(http://invalid.uri)
Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
(mailto:thomas.larsen@sanofi.com)
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
(mailto:alize.kaisserian@sanofi.com)
Arnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.com
(mailto:arnaud.delepine@sanofi.com)
Corentine Driancourt | + 33 6 40 56 92 21 | corentine.driancourt@sanofi.com
(mailto:corentine.driancourt@sanofi.com)
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
(mailto:felix.lauscher@sanofi.com)
Tarik Elgoutni| + 1 617 710 3587 | tarik.elgoutni@sanofi.com
(mailto:Tarik.Elgoutni@sanofi.com)
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
(mailto:nathalie.pham@sanofi.com)
Formation Bio Media Relations
press@formation.bio (mailto:press@formation.bio)
OpenAI Media Relations
Steve Sharpe | + 1 650 224 2362 | ssharpe@openai.com (mailto:ssharpe@openai.com)
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the fact that
product candidates if approved may not be commercially successful, the future
approval and commercial success of therapeutic alternatives, Sanofi's ability to
benefit from external growth opportunities, to complete related transactions
and/or obtain regulatory clearances, risks associated with intellectual property
and any related pending or future litigation and the ultimate outcome of such
litigation,? trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and subsequent
changes thereto, and the impact that pandemics or other global crises may have
on us, our customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees and on the
global economy as a whole. The risks and uncertainties also include the
uncertainties discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2023. Other than as required by
applicable law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
Â